← Back
Irulya Therapeutics
IRLA
$32.47
+1.48% on Oct 28
No insider trades reported for Irulya Therapeutics yet.
No insider trades or company news in this range.
2 reverse splits here, the latest 1-for-20 in Jun 2026. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what IRLA ever actually traded at. The drop is real, but those huge old numbers aren't.
Shares borrowed and sold by investors who expect the price to drop.
Planned sales
Form 144 notices filed for Irulya Therapeutics in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
CEO Dirk Thye filed to sell 3,700 shares on 21 Oct; no sale reported yetNotice on SEC.gov
All reports
Every insider trade and SEC report we hold for Irulya Therapeutics.
Newest first
No insider trades reported for IRLA yet.
Analysts, earnings and news
Analysts' price target
$75.00 average
8 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 4 quarters above
Q2 '26−$12.15 a share+$0.23
Q1 '26$57.60 a share+$109.60
Q4 '25−$152.00 a share−$107.00
Q3 '25−$50.00 a share−$5.50